Amgen Inc. (NASDAQ:AMGN) Stock Position Decreased by Facet Wealth Inc.

Facet Wealth Inc. cut its position in shares of Amgen Inc. (NASDAQ:AMGN) by 5.2% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 746 shares of the medical research company’s stock after selling 41 shares during the period. Facet Wealth Inc.’s holdings in Amgen were worth $194,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in the stock. Gitterman Wealth Management LLC acquired a new position in shares of Amgen during the 4th quarter valued at about $228,000. Centurion Wealth Management LLC grew its holdings in Amgen by 6.5% in the 4th quarter. Centurion Wealth Management LLC now owns 2,663 shares of the medical research company’s stock valued at $694,000 after buying an additional 163 shares during the last quarter. Diversified Enterprises LLC grew its holdings in Amgen by 12.4% in the 4th quarter. Diversified Enterprises LLC now owns 1,007 shares of the medical research company’s stock valued at $263,000 after buying an additional 111 shares during the last quarter. Clearstead Trust LLC grew its holdings in Amgen by 13.5% in the 4th quarter. Clearstead Trust LLC now owns 1,094 shares of the medical research company’s stock valued at $285,000 after buying an additional 130 shares during the last quarter. Finally, Greykasell Wealth Strategies Inc. acquired a new stake in Amgen in the 4th quarter valued at approximately $750,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen Trading Up 0.3 %

Shares of AMGN opened at $313.71 on Monday. The stock has a fifty day moving average price of $291.82 and a two-hundred day moving average price of $299.12. The company has a debt-to-equity ratio of 9.62, a quick ratio of 0.95 and a current ratio of 1.26. Amgen Inc. has a 52-week low of $253.30 and a 52-week high of $346.85. The company has a market cap of $168.53 billion, a price-to-earnings ratio of 41.55, a PEG ratio of 2.63 and a beta of 0.53.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, February 4th. The medical research company reported $5.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.04 by $0.27. Amgen had a return on equity of 176.32% and a net margin of 12.24%. Analysts predict that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, June 6th. Stockholders of record on Friday, May 16th will be paid a $2.38 dividend. The ex-dividend date of this dividend is Friday, May 16th. This represents a $9.52 annualized dividend and a dividend yield of 3.03%. Amgen’s dividend payout ratio (DPR) is currently 126.09%.

Insider Activity

In other news, EVP David M. Reese sold 25,225 shares of Amgen stock in a transaction on Friday, February 21st. The stock was sold at an average price of $304.44, for a total value of $7,679,499.00. Following the completion of the sale, the executive vice president now directly owns 36,922 shares of the company’s stock, valued at approximately $11,240,533.68. This trade represents a 40.59 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Nancy A. Grygiel sold 1,589 shares of Amgen stock in a transaction on Wednesday, February 5th. The stock was sold at an average price of $304.47, for a total value of $483,802.83. Following the sale, the senior vice president now directly owns 7,210 shares of the company’s stock, valued at approximately $2,195,228.70. This trade represents a 18.06 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 69,341 shares of company stock valued at $20,644,335. Company insiders own 0.69% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have issued reports on the company. Wells Fargo & Company reaffirmed an “equal weight” rating on shares of Amgen in a report on Wednesday, February 5th. Piper Sandler raised their target price on Amgen from $310.00 to $329.00 and gave the company an “overweight” rating in a report on Monday, February 10th. Leerink Partners lowered their target price on Amgen from $349.00 to $302.00 in a report on Wednesday, November 27th. Piper Sandler Companies reiterated an “overweight” rating and issued a $310.00 price objective on shares of Amgen in a research report on Thursday, January 2nd. Finally, Redburn Partners reduced their price objective on Amgen from $200.00 to $195.00 in a research report on Wednesday, November 27th. Two research analysts have rated the stock with a sell rating, ten have issued a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $314.04.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.